![]() |
|
|
Vol. 284, Issue 3, 1180-1187, March 1998
Institut National de la Santé et de la Recherche
Médicale Unité 367, Paris, France (O.C., J.A., J.M.,
F.A.-G.), and
Pharmacology Division, Hoffmann-La Roche, Basel,
Switzerland (J.-P.C.)
The concentration of angiotensin-converting enzyme (ACE) increases
during chronic treatment with ACE inhibitors for unknown reasons. We
investigated whether alterations in ACE mRNA and ACE concentration
occur in the different tissues during ACE inhibition and the role of
angiotensins in these regulations by comparing ACE inhibitors with
other blockers of the renin-angiotensin system. Enalapril, an ACE
inhibitor, in the range of 0.3 to 10 mg/kg/day in rats induced dose-
and time-dependant increases in plasma ACE up to two to three times
control values. There were significant increases in the steady state
ACE mRNA in the lung (32%), duodenum (64%) and aorta (324%) and 40%
to 140% increases in membrane-bound enzyme concentration in these
tissues and in the heart and kidney. The ACE content of purified
duodenal brush border was increased by 80%, but the enzyme and its
mRNA in the testis were not altered. The angiotensin II receptor
antagonist losartan at several regimens of up to 30 mg/kg twice a day
for 14 days produced no change in plasma ACE level or lung ACE mRNA.
The human renin inhibitor ciprokiren was tested in guinea pigs, a
species sensitive to this compound. Both enalapril and cilazapril
induced 2-fold increases in plasma ACE, but ciprokiren (24 mg/kg/day
for 12 days) had no effect. Enalapril treatment of BN/Kat rats (lacking
circulating kininogens) caused a similar increase in ACE as in other
rats. This study documents a general increase in ACE
gene expression and enzyme concentration in tissues during ACE
inhibition, with the exception of the testis, most probably reflecting
an activation of the 5
, so-called somatic promoter of the
ACE gene. Angiotensins are not involved in this
regulation and do not seem to control ACE gene expression in normal rodents.
This article has been cited by other articles:
![]() |
A. Nikzamir, M. Nakhjavani, A. Esteghamati, and A. Rashidi Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1274 - 1277. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Fleming Signaling by the Angiotensin-Converting Enzyme Circ. Res., April 14, 2006; 98(7): 887 - 896. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Fleming, K. Kohlstedt, and R. Busse New fACEs to the Renin-Angiotensin System Physiology, April 1, 2005; 20(2): 91 - 95. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kohlstedt, R. Busse, and I. Fleming Signaling via the Angiotensin-Converting Enzyme Enhances the Expression of Cyclooxygenase-2 in Endothelial Cells Hypertension, January 1, 2005; 45(1): 126 - 132. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kohlstedt, R. P. Brandes, W. Muller-Esterl, R. Busse, and I. Fleming Angiotensin-Converting Enzyme Is Involved in Outside-In Signaling in Endothelial Cells Circ. Res., January 9, 2004; 94(1): 60 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bardoux, D. G. Bichet, H. Martin, Y. Gallois, M. Marre, M.-F. Arthus, M. Lonergan, N. Ruel, N. Bouby, and L. Bankir Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system Nephrol. Dial. Transplant., March 1, 2003; 18(3): 497 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Huang, F. A. Gelas, and M. J. Osborne-Pellegrin Protection of the Arterial Internal Elastic Lamina by Inhibition of the Renin-Angiotensin System in the Rat Circ. Res., May 4, 1998; 82(8): 879 - 890. [Abstract] [Full Text] [PDF] |
||||